Showing 81 - 100 results of 51,961 for search '(( 50 ((nn decrease) OR (((teer decrease) OR (a decrease)))) ) OR ( a non decrease ))', query time: 0.95s Refine Results
  1. 81

    Lower insular perfusion in the DAT group compared with the non-DAT group. by Masashi Takeuchi (1930312)

    Published 2022
    “…In the region of interest-based analysis, decrease extent ratios were higher in the DAT group (N = 12) than in the non-DAT group (N = 38) (D). …”
  2. 82
  3. 83
  4. 84
  5. 85
  6. 86

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  7. 87

    VCP inhibition induces accumulation of ubiquitinated-proteins and decreases NFκB-expression. by Kyla Walworth (3150936)

    Published 2016
    “…The increase in ubiquitinated-protein accumulation in soluble protein-fraction suggests that the DDN<sup>DBeQ</sup> treatment alters VCP-function resulting in proteostasis-inhibition and ER-accumulation of these proteins. We also see a significant decrease in expression of tumor-mediator, NFκB in DDN/DDN<sup>DBeQ</sup> treated samples as compared to the control-vehicle, although DDN<sup>DBeQ</sup> was most effective as anticipated. …”
  8. 88

    Proliferative tissue degeneration is accompanied by a sustained decrease in proliferation, acute apoptotic responses, and progressive accumulation of DDR foci. by Catarina M. Henriques (102294)

    Published 2013
    “…Proliferative tissues such as A) testes, B) head kidney and C) gut sections show sustained significant decrease in proliferation in <i>tert<sup>−/−</sup></i> as compared to <i>tert<sup>+/+</sup></i> siblings (panels b, d and e) (p<0.001) and an acute apoptotic response at 3 months of age (p<0.001), which clears by c. 12 months (panels g, i and j). …”
  9. 89
  10. 90
  11. 91
  12. 92
  13. 93
  14. 94
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100